Early access
Sign in
Taking people in SpainPhase 1/2

Tests MK-4716 in adults with advanced solid tumors carrying KRAS changes

Tests MK-4716 in adults with advanced solid tumors that have KRAS changes.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Barcelona and Madrid, SpainSee the 3 sites
Trial code
Registry title
A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)
Status
Recruiting
Phase
Phase 1/2
People taking part
29 people, planned
Started
14 Jan 2026
Expected to end
5 Apr 2029
Type of study
Interventional
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic solid tumors that have a KRAS alteration, including people with first-line non-small cell lung cancer (1L NSCLC).

Age
18 years and older
Sex
All sexes can join.
Disease stage
Advanced or metastatic solid tumors, including first-line non-small cell lung cancer (1L NSCLC).
Biomarker or test result
A KRAS alteration (KRAS mutation or KRAS amplification).

Main reasons for not taking part

  • Healthy volunteers cannot join.

Where in Spain

  • Hospital Clinic de BarcelonaBarcelona, SpainTaking people
  • Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
  • Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests MK-4716 in adults with advanced solid tumors carrying KRAS changesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
3 November 2026